Registration
Members Log-In
Start Networking
Customer Service
Have a question about this event?
Customer Service representatives are available to help from 8 AM - 6 PM EST
Call 888-670-8200
Need Technical Assistance With this Website?
Send an email to IIR's Web Department
Agenda at a Glance
Vaccines Conference Agenda
| Conference Kick-Off Workshop: Wednesday, September 23th, 2009 | |
| 8:30 | Registration & Morning Coffee |
| 9:00 | Workshop Begins (See the Workshops page for details.) |
| 10:30 | 30 Minute Networking & Refreshment Break |
| 12:00 | Workshop Concludes; Luncheon for Workshop Participants Only |
| Main Conference, Day One: Wednesday, September 23th, 2009 | |
| 12:15 | Main Conference Registration |
| 1:00 | Chairperson’s Welcome & Opening Remarks Vu Truong-Le, Vice President of R&D, Aridis Pharma |
| Developing Innovative and Thermostable Vaccines | |
| 1:15 | Choosing the Appropriate Patient Population: Observations from Therapeutic Cancer Clinical Trials |
| 2:00 | Case Study: Stabilization of Vaccines and Other Biological Products |
| 2:45 | 30 Minute Networking & Refreshment Break |
| 3:15 | Case Study: Formulation and Stability Challenges for Virus Therapeutics: Above and Beyond Proteins Byeong S. Chang, PhD, Chief Scientific Officer, Integrity Bio |
| 4:00 | Case Study: Development and Clinical Manufacturing of a Platform Process for Plasmid DNA Vaccines Richard M. Schwartz, PhD, Chief, Vaccine Production Program, Vaccine Research Center, NIAID, NIH |
| 4:30 | Case Study: Strategies to Stabilize Complex Vaccines Vu Truong-Le, Vice President of R&D, Aridis Pharma |
| 5:00 | Day One Concludes |
| Main Conference, Day Two: Thursday, September 24th, 2009 | |
| 8:00 | Morning Coffee |
| 8:30 | Conference Chairperson’s Recap of Day One Vu Truong-Le, Vice President of R&D, Aridis Pharma |
| Novel Vaccine Delivery Advances | |
| 8:45 | Case Study: Vaccination Using Microneedles |
| 9:30 | PATH Evaluation of Microneedles for Use in Developing Country Vaccine Delivery Courtney Jarrahian, Technical Coordinator, Program for Apropriate Technology in Health (PATH) |
| 10:15 | 30 Minute Networking & Refreshment Break |
| 10:45 | Vaccine Potency Measurement: Challenges and Approaches Hersh Mehta, PhD, Head, Product Conception and Development, Sanofi-Pasteur |
| 11:30 | Keynote Presentation: Vaccinology: A Vaccines Historical Perspective and the Potential Impact on the Vaccines Business Arthur Allen, Author, Vaccine: the Controversial Story of Medicine’s Greatest Lifesaver |
| 12:15 | Luncheon |
| Adjuvants | |
| 1:15 | Case Study: An Adjuvant Status Update - Where Are We Now? Hedwig Kresse, Senior Analyst, Infectious Diseases, Datamonitor |
| 2:00 | Key Steps in the Development and Registration of an Adjuvanted Vaccine |
| 2:30 | Case Study: Boosting DNA Vaccines with Vaxfectin adjuvant |
| 3:00 | 30 Minute Networking & Refreshment Break |
| 3:30 | Injecting Biological Drugs and Vaccines in a Solid Dosage Form Charles Potter, PhD, Chief Executive Officer, Glide Pharma |
| 4:15 | Case Study: Analytical Method Development for Vaccines Vincent Turula, Wyeth Vaccines |
| 5:00 | Day Two Concludes |
| Main Conference, Day Three: Friday, September 25th, 2009 | |
| 8:00 | Morning Coffee |
| 8:45 | Conference Chairperson’s Recap of Day One Vu Truong-Le, Vice President of R&D, Aridis Pharma |
| Vaccine Immunogenicty & Potencey Testing | |
| 9:00 | Satisfying the Need for Innovative HIV Vaccine Strategies: A Novel Lentiviral Vector Vaccine Candidate Franck Lemiale, PhD, PharmD, Director, Vaccines & Immunology, VIRxSYS Corporation |
| 9:45 | Case Study: |
| 10:30 | 30 Minute Networking Break |
| 11:00 | Case Study: Meeting a Grand Challenge in Global Health: Safer, Needlefree, Unit-dose, Inhalable Dry Powder Vaccines Scott Winston, Aktiv-Dry |
| 11:45 | Your Choice of Sessions on Biologics & Biosimilars A Novel DNAi Being Developed for the Treatment of Cancer Wendi Rodriquez, Pronai Robert Forgery, President and COO, Pronai or Commercial and Public Sector Insurance Payment Issues, Future Trends & Perspectives F. Randy Vogenberg, PhD, Jefferson School of Population Health |
| 12:30 | Your Choice of Sessions on Biologics & Biosimilars Scale Up and Manufacture of SiRNA-Based Drugs Peter Lutwyche, PhD, VP of Pharmaceutical Development, Tekmira or Main Street Perspective: What Patients and Consumers Want from Biosimilars and Biogenerics Leigh Purvis, Policy Research Analyst, AARP Public Policy Institute |
| 1:15 | Close of the 2009 Vaccines Development Forum; See You Next Year! |
